Snake venom tissue-damaging toxins

Snake venom tissue-damaging toxins are a heterogeneous group of proteins and enzymes, primarily from the Viperidae and Elapidae families, that mediate the local and systemic morbidity of snakebite envenomation (Source 1.1.1, 1.1.4). This group includes major toxin families such as phospholipases A2 (PLA2), snake venom metalloproteinases (SVMP), snake venom serine proteases (SVSP), and cytotoxic three-finger toxins (3FTx) (Source 1.4.4). These toxins act through various mechanisms, including the hydrolysis of cell membrane phospholipids, degradation of the extracellular matrix and vascular basement membranes, and disruption of the coagulation cascade (Source 1.1.1, 1.1.2, 1.4.2). Pathologically, they cause myonecrosis, dermonecrosis, hemorrhage, and edema, often leading to permanent disability or systemic complications like acute kidney injury (Source 1.1.1, 1.5.2). While traditional treatment relies on intravenous antivenoms, emerging therapies focus on small-molecule inhibitors like varespladib and marimastat to provide rapid, pre-hospital intervention (Source 1.2.3, 1.3.1). The primary therapeutic challenges include the rapid, often irreversible progression of local tissue damage and the risk of severe allergic reactions to animal-derived antivenoms (Source 1.5.1, 1.5.5).

Other names

Cytotoxic and local tissue-damaging snake venom toxins from Viperidae, Elapidae, and related speciesSnake venom cytotoxinsTissue-damaging toxinsMyotoxinsHemorrhagic toxinsNecrotizing toxinsSnake venom necrotic toxins

Inhibition of enzymatic activity (PLA2, SVMP, SVSP), chelation of essential metal ions (e.g., Zn2+), and antibody-mediated neutralization of toxin epitopes.